HK
CASC

Horizon Kinetics’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Horizon Kinetics’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-5,556
Closed -$91K – 518
2015
Q3 		$91K Hold
5,556
– – ﹤0.01% 489
2015
Q2 		$125K Hold
5,556
– – ﹤0.01% 501
2015
Q1 		$54K Buy
5,556
+167
+3% +$1.64K ﹤0.01% 514
2014
Q4 		$61K Hold
5,389
– – ﹤0.01% 512
2014
Q3 		$62K Hold
5,389
– – ﹤0.01% 514
2014
Q2 		$105K Hold
5,389
– – ﹤0.01% 518
2014
Q1 		$97K Hold
5,389
– – ﹤0.01% 524
2013
Q4 		$57K Hold
5,389
– – ﹤0.01% 535
2013
Q3 		$67K Hold
5,389
– – ﹤0.01% 534
2013
Q2 		$51K Buy
+5,389
New +$69.2K ﹤0.01% 453

Other funds holding CASC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

Horizon Kinetics's CASC Position: Q4 2015 in Review

Horizon Kinetics sold out of Cascadian Therapeutics, Inc. (CASC) in Q4 2015, closing a stake of 5,556 shares — an estimated $91K sold.

Horizon Kinetics first reported a position in CASC in Q2 2013 and held it in 10 quarters. The position peaked at $125K in Q2 2015. 93 funds tracked by Wall St. Rank hold CASC as of Q4 2015.

  • Horizon Kinetics reported no remaining Cascadian Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
  • Horizon Kinetics sold 5,556 Cascadian Therapeutics, Inc. shares in Q4 2015, an estimated $91K.
  • Horizon Kinetics first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 10 quarters.
  • Horizon Kinetics's Cascadian Therapeutics, Inc. position peaked at $125K in Q2 2015.
  • 93 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q4 2015.

Based on Horizon Kinetics's 13F filing for Q4 2015, filed 12 Feb 2016.